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Giant cell bone lesions in the craniofacial region: a diagnostic and
therapeutic challenge
Bruno Barros Pinto Borges, MD1, Marco Aure´lio Fornazieri, MD1, Ana Paula Correia de Arau´jo Bezerra, MD1,
Leandro Aure´lio Liporoni Martins, MD2, Fa´bio de Rezende Pinna, MD, PhD3, Richard Louis Voegels,
MD, PhD3
Background: Giant cell tumors of bone (GCTs) are com-
mon in the long bones, but rare in the craniofacial region,
with only 1% of cases occurring in the laer. Clinical, ra-
diological, and anatomical diagnosis of this locally aggres-
sive disease, which occurs in response to trauma or neo-
plastic transformation, poses a major challenge in clinical
practice.
Methods: The present study describes a series of 4 cases
and highlights the main features of the diﬀerential diagno-
sis and treatment of these lesions: GCT, giant cell repar-
ative granuloma (GCRG), and the brown tumor of hyper-
parathyroidism.
Results: GCT presents as a benign neoplasm, most typically
aﬀecting the knees, and rarely in the temporal and sphe-
noid bones. It is radiologically indistinguishable from GCRG
due to its lytic, poorly deﬁned appearance. The distinc-
tion can only be made microscopically, as the presence of
multinucleated giant cells scaered throughout the stroma
and the absence of a history of trauma favor a diagnosis of
GCT. The brown tumor of hyperparathyroidism occurs with
rapid, localized osteoclast activity secondary to the eﬀects
of increased parathyroid hormone (PTH) levels; parathy-
roid examination is indispensable.
Conclusion: The diagnosis and treatment of these lesions
poses a major challenge due to their similar clinical pre-
sentation and radiological appearance. Accurate diagnosis
is essential for deﬁnition of appropriate management, as
complete resection is the goal in GCT and GCRG to avoid
recurrence, whereas the brown tumor oen yields to treat-
ment of the underlying hyperparathyroidism. C© 2012 ARS-
AAOA, LLC.
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Among the bone neoplasms that feature a giant cellcomponent, there are the true giant cell tumor of
bone (GCT), the giant cell reparative granuloma (GCRG),
and the brown tumor of hyperparathyroidism. When
found in the craniofacial region, these tumors share
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quite similar clinical, radiological, and histopathologic
features.
GCTs and GCRGs are considered benign neoplasms, but
may display expansive and locally destructive behavior.1
GCTs represent about 5% of all primary bone tumors and
20% of benign bone neoplasms.2 They characteristically
arise in the epiphyses of long bones such as the femur and
tibia; only 2% of GCTs are found in the head and neck.2
The local recurrence rate is approximately 25%, and in ap-
proximately 2% of patients, the tumor may metastasize to
the lungs.2,3 A history of local trauma or infection suggests
the diagnosis of GCRG, which also displays some poten-
tial for recurrence. The pathogenesis of GCRGs is believed
to be associated with a local reparative reaction, which
would make this tumor a reactive lesion rather than a true
neoplasm. GCRG occurs predominantly in the mandible,
and rarely affects the skull. It is most common in the first
2 decades of life, whereas GCT usually occurs in older
patients.4
1 International Forum of Allergy & Rhinology, Vol. 00, No. 0, Month/Month 2012
Borges et al.
The brown tumor occurs in 4.5% of cases of primary
hyperparathyroidism and 1.5% to 1.7% of patients with
secondary hyperparathyroidism.5 The most common loca-
tions are the ribcage, clavicle, and pelvis; when found in the
craniofacial region, it usually affects the mandible. Brown
tumors may occur at any age, but are most frequent in
patients older than 50 years.5 This neoplasm may be the
presenting sign of primary hyperparathyroidism, or may
arise in end-stage secondary hyperparathyroidism, forming
a challenging differential diagnosis with other giant cell le-
sions. Measurement of parathyroid hormone (PTH) and
serum calcium levels is absolutely essential for correct di-
agnosis.
This article describes 4 cases of GCTs of the craniofacial
region, highlighting the challenges of differential diagnosis
and the clinical, radiologic, and histopathologic features
of each of these neoplasms by means of a review of the
literature.
Case reports
Case 1
A 30-year-old female presented with a 6-month history of
nasal obstruction on the right. On fiber-optic nasal en-
doscopy, a friable, wine-colored lesion was found in the
right middle meatus. Computed tomography (CT) showed
a mass lesion involving the ethmoid region, with no in-
tracranial or orbital extension. Complete excision was per-
formed including wide antrostomy, ethmoidectomy, and
curettage of the underlying bone by endoscopic approach.
Subsequent histopathological examination revealed GCT.
After 5 years, the patient was disease-free.
Case 2
A 12-year-old female presented with a 3-month history of
left-sided swelling in the zygomatic area. CT showed a le-
sion involving the nasal fossa, maxillary sinus, palate, and
upper dental arch on the left (Fig. 1). After surgical resec-
tion, histopathological examination confirmed the diagnos-
tic hypothesis of GCRG (Fig. 2). Three subsequent surgeries
were required due to the recurring nature of the lesion. A
parathyroid scan revealed no abnormalities, and PTH, vita-
min D, and serum calcium levels were within normal limits.
The tumor has not recurred since the patient’s most recent
surgery, performed 3 years ago.
Case 3
A 45-year-old female reported a 4-month history of frontal
headache, nasal obstruction, proptosis, and declining visual
acuity on the left. Nasal endoscopy revealed a lesion in the
left sphenoethmoidal recess. CT and magnetic resonance
imaging (MRI) showed orbital and intracranial extension
(Fig. 3). The tumor was excised via a combined craniofacial
and neurosurgical approach, and subsequent histopatho-
logical examination was consistent with brown tumor
(Fig. 4). Figure 5 shows MRI after 1 month after surgery.
FIGURE 1. (A,B) GCRG (case 2): CT, axial view, bone window; hyperatten-
uating lesion with erosion of the anterior wall of the left maxillary sinus and
extension to the palatal bone. CT = computed tomography; GCBR = giant
cell reparative granuloma.
FIGURE 2. Histopathology of GCRG (case 2). H&E (×200) stained: arrows
points giant cells and the arrowhead area of hemorrhage. GCBR = giant cell
reparative granuloma; H&E = hematoxylin and eosin.
There is complete absence of lesion with intracranial and
orbital region free of injury. Serum PTH and calcium levels
were elevated, and neck ultrasound revealed a nodule on
a left parathyroid gland. The patient underwent parathy-
roidectomy, followed by immediate normalization of serum
PTH and calcium levels, and has remained disease-free after
24 months from surgery.
Case 4
A 70-year-old female presented with a 2-year history of
progressive right-sided nasal obstruction and recurrent
epistaxis. She eventually developed hyposmia, headache,
diplopia, and swelling below the right eyelid. Nasal en-
doscopy showed a bulging lateral wall of the right nostril.
Neuroimaging showed a mass lesion in the right maxillary
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FIGURE 3. (A) Brown tumor: MRI, coronal view, T2; heterogeneous lesion in the left ethmoid and sphenoid sinus, with intracranial and orbital invasion. (B)
Brown tumor: CT, coronal view, soft tissue window; heterogeneous lesion in the left ethmoid and sphenoid sinus, with intracranial extension. CT = computed
tomography; MRI = magnetic resonance imaging.
sinus with ipsilateral bulging of the orbital floor and nasal
fossa (Fig. 6). A fragment of the lesion was biopsied, and
subsequent analysis revealed exuberant granulation tissue
growth with foreign-body giant cell reaction. There was no
recent history of trauma or infection. Serum PTH, calcium,
and phosphorus levels were within normal limits. Complete
excision of the mass was performed via an endoscopic ap-
proach and histopathological examination of the surgical
specimen confirmed a diagnosis of granulomatous giant cell
reaction (GCRG). At the time of writing, 10 months after
surgery, the patient had recently presented for follow-up
with no complaints or signs of disease recurrence.
Discussion
GCRG was first described in 1953 by Jaffe,1,3,6,7 who
characterized it as a reactive lesion occurring secondary to
intraosseous hemorrhage. The pathogenesis of GCRG in-
volves a hyperplastic reparative reactionwith focal bleeding
FIGURE 4. Histopathology of brown tumor. H&E (×100) stained: arrows
points giant cells and arrowhead osteoid formation. H&E= hematoxylin and
eosin.
induced by trauma or infection.1,3,4,8 Nevertheless, a clear
history of trauma or infection cannot always be elicited,
and the true nature of this disease (particularly whether it
constitutes a true neoplasm or merely a reactive lesion) re-
mains controversial.1,6 The prevalence of GCRG is highest
in children and young women, although it has been known
to occur up to the seventh decade of life.6,8 The 2 cases of
GCRG in our series (cases 2 and 4) are representative of
this extreme age distribution: 1 patient was 12 years old,
and the other was 70 years old. Neither had a history of
recent trauma or local infection.
Most lesions arise in the premolar and molar regions of
the mandible (twice as common as in the maxilla), and
many cross the midline.7,8 When GCRG does occur in the
FIGURE 5. Visual outcome (case 3): 1 month after surgery.
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FIGURE 6. GCRG (case 4): MRI showing a mass lesion in the right maxillary
sinus. GCBR = giant cell reparative granuloma; MRI = magnetic resonance
imaging.
maxilla, it destroys the anterior region of the bone in 75%
of cases.6 Rarely, the tumor may affect the orbit, paranasal
sinuses (as described herein), cranial vault, temporal, sphe-
noid, or ethmoid bones, and small bones of the hands and
feet.4,6–8 Most GCRGs are asymptomatic; the most com-
mon presenting finding is painless bulging in the facial re-
gion or oral cavity, with no attendant paresthesia.6 Other
signs and symptoms may include facial asymmetry, nasal
obstruction, dental loss or displacement, and pathologic
fractures.6
The GCT is a benign neoplasm that occurs most fre-
quently in the long bones, particularly the distal femur and
radius and proximal tibia; the sacrum is the most com-
monly affected flat bone.2,3,6 The skull is affected in only
1% of cases, predominantly in the sphenoid and temporal
bones. Maxillary involvement is exceedingly rare.3,9 GCTs
present as single tumors, and may occur at any age; 20%
to 33% of patients are over the age of 50 years.3,9 Patient
1 in our series exemplifies a case of GCT in an extremely
unusual location: the ethmoidal labyrinth.
CT and MRI alone are unable to distinguish between
these lesions; clinical and histopathologic correlation is in-
dispensable, as seen in Table 1.
The histological distinction between these lesion types
depends on quite subtle differences. GCRGs feature gi-
ant spindle-shaped mononuclear cells that tend to clus-
ter around areas of abundant bone formation, prolifera-
tion of fibroblasts, and hemorrhagic foci with hemosiderin
deposition.1,6,8,10 The presence of bonemetaplasia is highly
suggestive of GCRG.10 In GCTs, cells are multinuclear,
round or ovoid, and more uniformly distributed, and there
is no bone neoformation. There are fewer foci of osteoid
tissue, hemorrhage, and fibrosis, and little hemosiderin
deposition.1,6,10 Mitotic cells and focal necrosis are found
in GCTs, but not in GCRGs.4 The mononuclear stromal
cells of GCTs are strongly positive for the p63 protein on
immunohistochemical analysis, which yields no findings of
note in GCRGs. Expression of p63 can help distinguish be-
tween these lesions, and also suggests their pathogenesis is
different.7
In the surgical management of GCRG and GCT, com-
plete resection is always the goal, as it enables cure. Local
curettage of GCRGs is associated with a cure rate of 80%.6
GCRGs are quite highly vascularized lesions, and substan-
tial intraoperative blood loss may occur during surgical
intervention; it is recommended that blood products be
banked or set aside prior to the procedure.6 Some nonsur-
gical treatment modalities may also be attempted in small,
slow-growing GCRGs, such as interferon alfa, calcitonin,
and intralesional corticosteroids.6,7
When complete resection of a GCT is not possible, adju-
vant radiation therapy is indicated, despite the possibility of
sarcomatous transformation.1,2 Radiation therapy should
not be attempted until all possibility of surgical treatment
has been exhausted.1 Chemotherapy is reserved for cases
in which surgery and radiation therapy have failed to pro-
vide adequate tumor control, and consists of a combination
regimen of methotrexate, doxorubicin (Adriamycin), and
cyclophosphamide.3
In terms of prognosis, GCT is markedly distinct from
GCRG in that the former has the potential for malignant
transformation, a high recurrence rate (25%), and may
metastasize, particularly to the lungs, in 2% of cases.1,3
When only partial resection can be accomplished, the recur-
rence rate of GCT increases to 40% to 60%.2 Conversely,
GCRG has a low recurrence rate, in the region of 10% to
15%, and metastases have never been reported.1,3,6,9
Follow-up of GCT patients is required because 80% to
90% of tumor recurrences arise within 3 years of primary
treatment. Therefore, follow-up visits are recommended ev-
ery 4 months in the first 2 years after surgery and every 6
months thereafter until the fifth year.2 Long-term follow-
up is also mandatory, as delayed remote metastases have
been reported.2 The prognosis for patients with malignant
GCT is very poor, with most dying within a year.3 Ma-
lignant transformation is most commonly to fibrosarcoma,
osteosarcoma, or malignant fibrous histiocytoma.1
The brown tumor of hyperparathyroidism is usually a
manifestation of the secondary form of this condition in
patients with advanced chronic kidney disease.5,6 It may,
however, constitute the presenting symptom of primary hy-
perparathyroidism in patients with no other clinical signs
or symptoms of parathyroid dysfunction. In most primary
cases, hypercalcemia and hypophosphatemia are found in-
cidentally on routine blood work, with imaging revealing a
parathyroid adenoma in 85% of patients.11 Like the GCT,
the brown tumor may occur at any age; it is most common
among patients older than 50 years, and is approximately
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TABLE 1. Comparison of clinical and laboratory features of giant cell bone lesions
GCRG GCT Brown tumor
Age <20 years 20 to 40 years Any; most commonly >50 years
Location Mandible, maxilla Long-bone epiphyses; rarely
affects sphenoid, temporal bone
Ribs, clavicle, pelvis
Histopathology findings 1. Giant cells around a focus of
hemorrhage
1. Uniformly scattered giant cells 1. Osteoclast-like multinucleated
giant cells
2. Evidence of bleeding and, in
long-standing lesions,
hemosiderin deposition
2. Bleeding is unusual;
hemosiderin deposition is rare,
and minor when present
2. Bleeding and hemosiderin-
laden macrophages
3. Small, irregular, elongated,
oligonucleated giant cells
3. Large, round, multinucleated
giant cells
3. Dense fibroblastic stroma, cystic
degeneration, osteoid
formation, microfractures
4. Focal osteoid and bone
neoformation enmeshed in the
lesion
4. Bone neoformation is
uncommon
Serum PTH and calcium
levels
Within normal limits Within normal limits High
CT/MRI factures CT: Bone destruction and potential
extension into the surrounding
soft tissues; MRI: T1
hypointensity and T2
hyperintensity with variable
internal septation
CT: Lytic expansile lesion with a
thin cortical layer and inner
sclerosis; MRI: low to moderate
signal intensity on T1 and T2
imaging due to its high collagen
content
CT: Well-circumscribed lytic lesion
stimulating reactive bone
formation; MRI: hypointense
areas on T1 and T2
corresponding to hemorrhagic
foci, and homogeneous
contrast enhancement with
multiple focal areas of low
signal intensity
Management steps Complete surgical resection by
local curettage
Complete surgical resection;
adjuvant radiation therapy when
surgical treatment has been
exhausted
Normalization of serum PTH,
calcium and phosphorus levels.
Resection if the brown tumor
continues to grow even after
hyperparathyroidism has been
controlled
Prognosis Low recurrence rate. To date, no
documented metastasis and
malignant transformation
High recurrence rate if a radical
resection is not performed.
Potential for malignant
transformation and metastasis
No potential for malignant
transformation and low
recurrence rate after
hyperparathyroidism has been
controlled
CT = computed tomography; GCRG = giant cell reparative granuloma; GCT = giant cell tumor of the bone; MRI = magnetic resonance imaging; PTH = parathyroid
hormone.
3 times as prevalent in women as in men.5 The most fre-
quent sites are the ribs, clavicle, and pelvis. The mandible
is affected in only 4.5% of cases.5,12 Spinal and maxil-
lary involvement are also considered rare, although reports
of cases occurring in these sites have increased in recent
years.12
The brown tumor is painless, but may lead to patho-
logic fractures and spinal cord compression when occur-
ring in the vertebral column.12 When found in the facial
region, they may produce disfiguring deformities and dif-
ficulty breathing and eating. Brown tumors are soft and
elastic to palpation.12
The diagnosis of brown tumor is based on clinical and
laboratory findings indicative of hyperparathyroidism, as
this lesion is radiologically and histologically similar to
both GCT and GCRG5 (Table 1). Brown tumors are ero-
sive bone lesions caused by osteoclast-like activity and per-
itrabecular fibrosis, leading to intense local destruction.12
Dense fibroblastic stroma, areas of cystic degeneration,
osteoid foci, microfractures, bleeding, hemosiderin-laden
macrophages, and osteoclast-like multinucleated giant cells
are the main histology findings, which do not enable clear
distinction between the brown tumor and other giant cell
lesions.5 Nevertheless, the brown tumor of hyperparathy-
roidism features a combination of osteoblast and osteoclast
activity. GCTs are often of a more infiltrative nature and
usually exhibit some degree of atypia as compared to brown
tumors, while GCRGs have a less dense and more highly
vascularized stroma.5
Treatment of the brown tumor of hyperparathyroidism
requires normalization of serum PTH, calcium, and phos-
phorus levels prior to any surgical procedure. Resolu-
tion of the lesion is expected after gland function has
stabilized. In some patients, however, the brown tumor
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continues to grow even after hyperparathyroidism has been
controlled; in these cases, resection is mandatory.5,12 The
brown tumor is considered a reparative granuloma rather
than a true neoplasm, and has no potential for malignant
transformation.12
When chronic kidney disease and a clinical picture indica-
tive of secondary hyperparathyroidism are present, biopsy
of the lesion is unnecessary. Conversely, the brown tumor
is exceedingly rare as a manifestation of primary hyper-
parathyroidism; in such cases, biopsy is mandatory, as the
lesion may in fact be the presenting finding of underlying
parathyroid dysfunction.5,12 Patient 3 in our series initially
underwent excisional biopsy of the lesion, as there were
no clinical signs of hyperparathyroidism, which decreased
clinical suspicion of a brown tumor. This case exemplifies
the challenges of diagnosing this lesion in patients with pri-
mary hyperparathyroidism when there are no overt clinical
manifestations of parathyroid dysfunction.
Other bone lesions that feature a giant cell component
and aggressive behavior and may thus be included in the
differential diagnosis are aneurysmal bone cyst, ossifying
fibroma, fibrous dysplasia, cherubism, chondroblastoma,
and osteosarcoma.1–3,6,10
Conclusion
The clinical cases described herein illustrate the com-
plexity of the differential diagnosis of giant cell le-
sions of bone, particularly when affecting the craniofacial
region.
Due to this highly challenging differential diagnosis,
knowledge of the main features of each distinct form of
giant cell tumor is particularly important to otolaryngol-
ogists and head and neck surgeons. Detailed clinical, ra-
diologic, and histopathologic examination can reveal the
optimal course of treatment for each case, always having
complete resection of the tumor and complete cure as the
target objectives.
References
1. Mohammed TL, Brummett DP, Hahn FJ, Sharma P.
Intracranial giant cell reparative granuloma arising
from the temporal lobe area: MR findings. AJNR Am
J Neuroradiol. 2001;22:873–875.
2. Marioni G, Marchese-Ragona R, Guarda-Nardini L,
et al. Giant cell tumour (central giant cell lesion) of
the maxilla. Acta Otolaryngol. 2006;126:779–781.
3. Saw S, Thomas N, Gleeson MJ, et al. Giant cell tu-
mour and central giant cell reparative granuloma of
the skull: do these represent ends of a spectrum? A
case report and literature review. Pathol Oncol Res.
2009;15:291–295.
4. Matsui T, Iwamuro K, Ishikawa T, et al. Large giant
cell reparative granuloma of the petrous bone–case
report. Neurol Med Chir (Tokyo). 2002;42:232–236.
5. Company MM, Ramos R. Giant cell tumor of the
sphenoid. Arch Neurol. 2009;66:134–135.
6. Orhan E, Erol S, Deren O, et al. Idiopathic bilateral
central giant cell reparative granuloma of jaws: a case
report and literature review. Int J Pediatr Otorhino-
laryngol. 2010;74:547–552.
7. Bilodeau E, Chowdhury K, Collins B. A case of recur-
rent multifocal central giant cell granulomas. Head
Neck Pathol. 2009;3:174–178.
8. Gandara-Rey JM, Pacheco Martins Carneiro JL,
Gandara-Vila P, et al. Peripheral giant-cell granu-
loma. Review of 13 cases. Med Oral. 2002;7:254–
259.
9. Proimos E, Chimona TS, Tamiolakis D, et al. Brown
tumor of the maxillary sinus in a patient with pri-
mary hyperparathyroidism: a case report. J Med Case
Reports. 2009;3:7495.
10. Wolfe JT 3rd, Scheithauer BW, Dahlin DC. Giant-cell
tumor of the sphenoid bone. Review of 10 cases. J
Neurosurg. 1983;59:322–327.
11. Triantafillidou K, Zouloumis L, Karakinaris G,
et al. Brown tumors of the jaws associated with pri-
mary or secondary hyperparathyroidism. A clinical
study and review of the literature. Am J Otolaryngol.
2006;27:281–286.
12. Leal CT, Lacativa PG, Gomes EM, et al. Surgical ap-
proach and clinical outcome of a deforming brown
tumor at the maxilla in a patient with secondary hy-
perparathyroidism due to chronic renal failure. Arq
Bras Endocrinol Metabol. 2006;50:963–967.
International Forum of Allergy & Rhinology, Vol. 00, No. 0, Month/Month 2012 6
